Skip to main content

Advertisement

Table 2 Descriptive characteristics of propensity score matched total hip replacement (THR) patients according to red blood cell transfusion within 8 days of surgery.

From: Allogeneic blood transfusion and prognosis following total hip replacement: a population-based follow up study

  Transfusion n = 2,254 No transfusion n = 2,254 Standardized mean difference***
Age (years)    
10-49 146 (6.5%) 159 (7.1%) 0.07561
50-59 272 (12.1%) 256 (11.4%) 0.03827
60-69 602 (26.7%) 635 (28.2%) 0.07124
70-79 830 (36.8%) 793 (35.2%) 0.00596
+80 404 (17.9%) 411 (18.2%) 0.18397
Sex    
Female 1,490 (66.1%) 1,439 (63.8%) 0.11293
Primary hip diagnosis    
Primary arthrosis 1,647 (73.1%) 1,633 (72.5%) 0.23293
Trauma 323 (14.3%) 319 (14.2%) 0.28662
Other 284 (12.6%) 302 (13.4%) 0.00682
Comorbidity history (yes)    
Myocardial infarction 104 (4.6%) 113 (5.0%) 0.02865
Congestive heart failure 116 (5.2%) 125 (5.6%) 0.08273
Peripheral vascular disease 97 (4.3%) 95 (4.2%) 0.02495
Cerebrovascular disease 172 (7.6%) 172 (7.6%) 0.11255
Dementia 15 (0.7%) 8 (0.4%) 0.10249
Chronic pulmonary disease 192 (8.5%) 176 (7.8%) 0.06104
Connective tissue disease 169 (7.5%) 161 (7.1%) 0.02309
Peptic ulcer disease 129 (5.7%) 129 (5.7%) 0.07967
Mild liver disease 37 (1.6%) 30 (1.3%) 0.04168
Diabetes (type I and II) 134 (5.9%) 115 (5.1%) 0.05238
Hemiplegia 4 (0.2%) 6 (0.3%) 0.03791
Moderate to severe renal disease 55 (2.4%) 60 (2.7%) 0.06410
Diabetes with end organ damage 61 (2.7%) 47 (2.1%) 0.06301
Any tumor 260 (11.5%) 235 (10.4%) 0.09151
Leukemia 10 (0.4%) 6 (0.3%) 0.04010
Lymphoma 18 (0.8%) 14 (0.6%) 0.04218
Moderate to severe liver disease 11 (0.5%) 12 (0.5%) 0.03710
Metastatic solid tumor 39 (1.7%) 26 (1.2%) 0.08036
Fixation technique    
Cemented 1,186 (52.6%) 1,175 (52.1%) 0.03568
Cementless 523 (23.2%) 522 (23.2%) 0.05074
Hybrid 545 (24.2%) 557 (24.7%) 0.01191
Type of anesthesia    
Regional 1,753 (77.8%) 1,757 (78.0%) 0.18378
Duration of surgery (minutes)    
0-60 418 (18.5%) 426 (18.9%) 0.09806
61-120 1,685 (74.8%) 1671 (74.1%) 0.03567
>121 151 (6.7%) 157 (7.0%) 0.20997
20 hospitals performing the THR procedures*   
Prophylaxis for heterotopic bone formation **   
Yes 195 (8.7%) 208 (9.2%) 0.06109
No 2059 (91.4%) 2046 (90.7%) 0.06268
Preoperative Hemoglobin concentration within three months prior to surgery   
<138.5 g/L 1410 (62.6%) 1362 (60.4%) 0.25041
>138.5 g/L 844 (37.4%) 892 (39.6%) 0.25041
Year of surgery    
1999 61 (2.7%) 58 (2.6% 0.03572
2000 60 (2.7%) 56 (2.5%) 0.06520
2001 94 (4.2%) 93 (4.1%) 0.02234
2002 309 (13.7%) 333 (14.8%) 0.02030
2003 239 (10.6%) 254 (11.3% 0.00876
2004 377 (16.7%) 392 (17.4%) 0.04756
2005 347 (15.4%) 333 (14.8%) 0.01024
2006 435 (19.3%) 411 (18.2%) 0.01185
2007 332 (14.7%) 324 (14.4%) 0.00976
  1. Data are shown in number (%) unless otherwise specified. *Good balance between groups for each of the 20 hospitals included in the propensity score was achieved in general. ** Anti -rheumatic drugs were used as prophylaxis for heterotopic bone formation. *** A standardized mean difference that exceeds 0.1 is indicative of significant imbalance between groups.